PMID- 33095928
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 46
IP  - 1
DP  - 2021 Feb
TI  - The role of pro-, pre- and symbiotics in cancer: A systematic review.
PG  - 50-65
LID - 10.1111/jcpt.13292 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Cancer is one of the most important causes of 
      morbidity and mortality worldwide. Pro-, pre- and symbiotics can modulate host 
      metabolism and gut microbiota and potentially help prevent cancer and modulate 
      the adverse effects (AEs) of treatments. Numerous studies on this role for pro-, 
      pre- and symbiotics have reported inconsistent results. The purpose of this 
      review was to examine current scientific evidence from randomized controlled 
      trials (RCTs) on the effects of pro-, pre- and symbiotics on the incidence of 
      complications and AEs, especially diarrhoea, in cancer management. METHODS: A 
      systematic literature search was implemented in MEDLINE using the MeSH terms 
      "probiotics", "prebiotics", "symbiotics" and "neoplasms", according to PRISMA 
      guidelines. Reference lists were also handsearched to identify additional 
      eligible RCTs. Three reviewers independently assessed the eligibility of each 
      RCT. Of 714 retrieved abstracts, 22 articles with 2287 participants were included 
      in the analysis. RESULTS AND DISCUSSION: The most studied bacteriotherapies were 
      probiotics and symbiotics, in 10 and 7 studies, respectively. Both Lactobacillus 
      and Bifidobacterium strains were used in 18 studies, while Lactobacillus and 
      Bifidobacterium strains were individually used in 9 and 2 studies, respectively. 
      Diarrhoea incidence rates were 3.2%-39.1% in intervention groups and 6.7%-60.9% 
      in control groups, while infection incidence rates were 11.1%-22.7% in 
      intervention groups and 17.3%-28.7% in control groups. WHAT IS NEW AND 
      CONCLUSIONS: Pro-, pre- and symbiotics may potentially be efficacious in reducing 
      complications associated with chemotherapy, radiotherapy and surgery in patients 
      with cancer.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Miarons, Marta
AU  - Miarons M
AUID- ORCID: 0000-0002-4129-4848
AD  - Pharmacy Department, Vall d'Hebron Hospital, Barcelona, Spain.
AD  - Pharmacy Department, Mataro Hospital, Barcelona, Spain.
FAU - Roca, Maria
AU  - Roca M
AD  - Nutrition Department, Mataro Hospital, Barcelona, Spain.
FAU - Salva, Francesc
AU  - Salva F
AD  - Oncology Department, Mataro Hospital, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201023
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Prebiotics)
SB  - IM
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Prebiotics/*administration & dosage
MH  - Probiotics/*administration & dosage
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - cancer
OT  - oncology diseases
OT  - prebiotics
OT  - probiotics
OT  - symbiotics
OT  - systematic review
EDAT- 2020/10/24 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/10/23 17:10
PHST- 2020/05/23 00:00 [received]
PHST- 2020/09/14 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2020/10/23 17:10 [entrez]
AID - 10.1111/jcpt.13292 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2021 Feb;46(1):50-65. doi: 10.1111/jcpt.13292. Epub 2020 Oct 
      23.